Resultado da Busca
For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences in Europe.
The ‘new normal’ involves partnerships and licensing, especially in Europe, while the M&A wave is not building as fast as once predicted. European Biotechnology reports in English on political, economic and technical development, covering the life sciences in the European Union
H4/2022 offers a whole series of exciting opportunities to reactivate professional contacts that have fallen asleep due to the pandemic and to expand your own network. Where to meet potential new partners and how to widen one’s scope beyond well-known terrain can be quite difficult to determine.
5 de dez. de 2022 · Here we list all biopharmaceuticals approved from January 2018 to June 2022, examining what types of product reached the US and EU markets as well as the indication for which they were...
WELCOME FROM THE CONGRESS ORGANISING COMMITTEE. The over-arching theme for the 2024 Congress will be “Grand Challenges for Biotechnology: Health; Food Security; and Global Warming”. To meet these challenges will require close cooperation between Industry, Academia, Research Institutes and national governments.
11 de out. de 2022 · Total capital raised through biotech IPOs worldwide in fourth quarter 2021 and first quarter 2022 fell by 63 percent compared with the same period a year before. 1 This trend is not unique to biotech; other innovative sectors that boomed over the past two years have experienced similar pullbacks.
The year in review. After a huge revenue surge in 2021, driven by the booming market for COVID-19 vaccines, therapies and testing, biotech’s growth normalized in 2022. Public biotech companies in the US and Europe collectively amassed revenues of US$215 billion in 2022, down 1% from the previous year (see Figure 1).
